Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rapacuronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.71 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.71 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.70 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | RAD52 | P43351 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rapacuronium SCHEMBL10699459 | 1.00 | SLC22A2 (0.71) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Rapacuronium SCHEMBL9094653 | 1.00 | SLC22A2 (0.71) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Rapacuronium SCHEMBL1650924 | 1.00 | SLC22A2 (0.71) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Rapacuronium SCHEMBL16977930 | 0.99 | KCNH2 (0.71) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Bromide SCHEMBL10698649 | 0.97 | SLC22A2 (0.71) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Bromide SCHEMBL10698645 | 0.97 | SLC22A2 (0.71) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Bromide SCHEMBL10700198 | 0.96 | SLC22A2 (0.65) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Bromide SCHEMBL10700202 | 0.96 | SLC22A2 (0.65) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Bromide SCHEMBL9643525 | 0.95 | KCNH2 (0.77) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 | |
| Bromide SCHEMBL9643530 | 0.95 | KCNH2 (0.77) | SLC22A2SLC47A2SLC47A1KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4154879-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | KOREA INST SCI & TECH (KR) | 2025-09-10 | — | — | EP | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4178948-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | Universidade de Santiago de Compostela (ES) | 2023-05-17 | — | — | EP | claimed |
| EP-4154879-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NICOTINE WITHDRAWAL SYMPTOMS | Korea Institute of Science and Technology (KR) | 2023-03-29 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | Avior, Inc. (US) | 2022-05-03 | — | — | US | claimed |
| WO-2022023496-A2 | FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2022-02-03 | — | — | WO | claimed |
| US-20210085622-A1 | TRANSMUCOSAL FILM COMPOSITION AND METHODS OF MAKING AND USING THE SAME | Avior, Inc. | 2021-03-25 | — | — | US | claimed |
| US-20210030693-A1 | PHARMACEUTICAL ACTIVE-CONTAINING FILM DELIVERY DEVICE FOR ORAL TRANSMUCOSAL ADMINISTRATION | Avior, Inc. | 2021-02-04 | — | — | US | claimed |
| EP-3755310-A1 | TRANSMUCOSAL FILM COMPOSITION AND METHODS OF MAKING AND USING THE SAME | Avior, Inc. (US) | 2020-12-30 | — | — | EP | claimed |
| US-20030077227-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system | NOVADEL PHARMA INC. | 2003-04-24 | — | — | US | claimed |
| CN-1402737-A | 6-mercapto-cyclodextrin derivs.: resersal agent for drug-induced neuromuscular block | AKZO NOBEL NV (NL) | 2003-03-12 | — | — | CN | claimed |
| EP-1259550-A1 | 6-MERCAPTO-CYCLODEXTRIN DERIVATIVES: REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK | Akzo Nobel N.V. (NL) | 2002-11-27 | — | — | EP | claimed |
| CN-1370073-A | Use of chemical chelators as reversal agents for drug-induced neuromuscular block | AKZO NOBEL NV (NL) | 2002-09-18 | — | — | CN | claimed |
| WO-2002064635-A1 | 2-ALKYLATED-CYCLODEXTRIN DERIVATIVES: REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK | AKZO NOBEL N.V. (NL) | 2002-08-22 | — | — | WO | claimed |
| EP-1210090-A2 | USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK | Akzo Nobel N.V. (NL) | 2002-06-05 | — | — | EP | claimed |
| EP-1150715-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2001-11-07 | — | — | EP | claimed |
| WO-2001040316-A1 | 6-MERCAPTO-CYCLODEXTRIN DERIVATIVES: REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK | AKZO NOBEL N.V. (NL) | 2001-06-07 | — | — | WO | claimed |
| WO-2001012202-A2 | USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG-INDUCED NEUROMUSCULAR BLOCK | AKZO NOBEL N.V. (NL) | 2001-02-22 | — | — | WO | claimed |
| WO-2000045846-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | SANOFI-SYNTHELABO (FR) | 2000-08-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030693-A1 | PHARMACEUTICAL ACTIVE-CONTAINING FILM DELIVERY DEVICE FOR ORAL TRANSMUCOSAL ADMINISTRATION | TAS2R42, TAS2R39, TAS2R45 | SLC22A2 98/4885SLC47A2 397/4885SLC47A1 314/4885 |
| US-11318107-B2 | Pharmaceutical active-containing film delivery device for oral transmucosal administration | TAS2R42, TAS2R39, TAS2R45 | SLC22A2 98/4885SLC47A2 397/4885SLC47A1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.